Dianthus Therapeutics investment exit

What happened: On April 9, 2026, Dianthus Therapeutics' CFO sold 8,224 shares, worth around $739,000, completely divesting his direct common stock holdings. Earlier, on March 31, he sold 114,367 shares, valued at approximately $9.49 million, exercising options to do so. Meanwhile, 5AM Venture Management exited its Dianthus position in Q4 2025, selling 365,053 shares and realizing a $14.36 million gain.

Market impact: These sales represent significant exits by early backers, potentially indicating a shift in investor sentiment towards Dianthus. The CFO's divestment could signal a change in insider confidence, while 5AM's full exit suggests a strategic decision to reallocate capital. This may impact Dianthus' stock valuation and investor perception.

What to watch next: Dianthus' Q1 2026 earnings report, scheduled for May 15, 2026, will provide insights into the company's financial health and growth prospects. Additionally, any regulatory updates on Dianthus' pipeline drugs, particularly DTX-001, will be crucial, as they could validate or challenge the recent investor exits. Lastly, the company's share price reaction to these developments will be telling, with key resistance levels around $90 and support at $80.